Direct-acting antiviral (DAA) medicines plays an important role in treatment of hepatitis C virus infection. It targets the hepatitis C virus in different ways to prevent it from self-multiplication. Direct-acting antivirals provides cure in shorter time with high cure rate and less side effects.

There are four classes of direct-acting antivirals viz. NS3/4A Protease Inhibitors, Nucleoside and Nucleotide NS5B Polymerase Inhibitors, NS5A Inhibitors, and Non-Nucleoside NS5B Polymerase Inhibitors. These all combines in different ways to make up the different hepatitis C DAA treatments.

Introduction of new direct-acting antivirals in the market is a major factor driving growth of the global direct-acting antiviral medicines market. Also, increasing prevalence of hepatocellular carcinoma and liver cirrhosis is another major factor propelling growth of the target market.

However, possible side effects of direct-acting antivirals is a major factor hampering growth of the global direct-acting antiviral medicine market.

The global direct-acting antiviral medicines market has been segmented on the basis of drug class, sales channel, and region.

On the basis of drug class, the global direct-acting antiviral medicines market has been segmented into NS3/4A Protease Inhibitors, Nucleoside and Nucleotide NS5B Polymerase Inhibitors, NS5A Inhibitors, and Non-Nucleoside NS5B Polymerase Inhibitors.

Request for the Sample Report Here: https://marketresearch.biz/report/direct-acting-antiviral-medicines-market/request-sample/

On the basis of sales channel, the global direct-acting antiviral medicines market has been segmented into hospital pharmacies, retail pharmacies and others (E-pharmacies, E-commerce, and drug stores).

Regional segmentation includes North America, Europe, Latin America, Asia Pacific and Middle East & Africa. North America contributes major market share followed by Europe and expected to maintain its dominance over the forecast period owing to presence of leading market players as well as high awareness about direct-acting antivirals among healthcare professionals in the region. Asia Pacific region is expected to witness rapid growth over the forecast period.

Some prominent players in the global direct-acting antiviral medicines market includes AbbVie, Inc., Bristol-Myers Squibb, Merck & Co., Vertex Pharmaceuticals, Inc., Janssen Therapeutics, and Gilead Sciences, Inc.